reason report
recap strong close year end-market
continu deliv
bottom line remain op-rat view
compani life scienc tool leader unmatch scale
access multipl grow end market arm
deliv organ revenu growth vs us street
estim even account fewer sell day
out-perform across segment end-market remain
healthi pharma deliv organ growth diagnost
academ segment came high-singl digit industri end-
market post mid-singl digit growth fei organ lc-m
instrument contribut strongli quarter specialti diagnost
recov clinic trial logist busi return growth
quarter contribut strength lab product servic lp
guid also came street help drive stock
higher pt increas back higher
guid reflect estim valuat
growth strong across busi segment
instrument servic deliv analyt technolog
deliv strong organ growth driven electron
microscopi lc-m high-end instrument instrument rang
genet test research biomark contribut strongli
quarter go forward also expect solid book fei
contribut robust backlog obitrap franchis
continu post growth lc-m well specialti diagnost grew
organ quarter driven stronger-than-usu flu season
biopharma end-market deliv organ growth larg driven
bioproduct analyt instrument improv clinic trial
servic biopharma remain core growth engin
overal life scienc tool sector patheon even
entrench segment believ outlook remain robust
mix anoth big contributor deliv mid-teen growth
emerg market repres revenu china
appear experienc growth across market
encourag despit tougher comp multi-year increas
lp segment perform driven recoveri clinic trial
servic busi lab product servic busi hold
distribut channel patheon grow clinic trial servic
busi post growth anniversari loss major
clinic trial servic contract drive segment higher
given guid revenues/ep estim
earlier
net debt total capit
price-to-earnings lt ep growth
life scienc tool diagnost
compani inform leerink partner llc research
revenu ep exclud charg amort intang
pleas refer page import disclosur price chart analyst certif
rate thermo fisher scientif outperform price target
remain outperform-r given view compani life scienc tool
lst leader unmatch scale reach research lab market combin
number growth product serv key end-market also consolid view
consolid sizabl portion lst market patheon acquisit close
believ potenti consolid contract develop manufactur
organ industri long term view posit given sheer
scale reput presenc lst market biopharma academ channel
industrial/environment diagnost deliv manag forecast grow
solidifi presenc emerg market asia-pacif china
revenu continu strength biopharma end-market view sign slow
near term inorgan growth continu remain key prioriti next
year capit deploy estim suggest
debt/ebitda leverag longer term also cogniz amzn penetr lab
suppli channel stronghold merger fisher scientif
share current trade ev/ebitda discount large-
mid-cap tool averag ev/ebitda
given continu exposur tailwind biopharma china believ hold
posit lead lab tool suppli provid howev entri lab
suppli busi despit earli stage lend caution expect
trade line peer group ev/ebitda multipl result deriv
price target appli multipl ebitda estim
primari risk price target includ
slowdown global budget research could caus downsid risk forecast
tighten budget govern academ fund could result lower revenu
rel estim furthermor restrict global budget could result shift focu
strategi growth could increas oper risk declin government spend
could risk downsid forecast growth nih spend
biopharma declin pose greatest risk tmo revenu declin biopharma fund
could highli impact revenu given third revenu lever biopharma
industri slowdown biopharma fund would result downsid risk estim
valuat biomolecul forecast ramp drug market mid-teen
estim hing prolifer drive use tmo bioprocess
equip mass spectromet instrument reagent character
scale diversif could backfir tmo size diversif
advantag compani consolid space pose signific challeng term
move needl growth perspect given size acquisit
alreadi done includ life pthn transact would ventur estim
deal size least grow north organ make signific move
market although asset might visibl street given limit public
asset larg number privat asset could potenti avail howev
pose risk street might appreci capabl asset enough
move needl
emerg market pose signific risk tmo revenu geopolit risk
emerg market could disrupt oper downsid risk valuat forecast
risk could countri region specif could also impact tmo strategi creat
higher barrier entri exist futur market local product reagent prefer
import oper numer intern market includ india
china eastern europ name
tmo exposur china could also pose concentr risk china repres
tmo revenu macroeconom impact chines market could lead declin
compani revenu regul chines polici could also caus restrict oper
lead lower activ china question remain china relat
detail headwind could emerg polici risk
 synergi may go plan tmo acquisit sizabl may go
plan could result integr risk lower-than-expect synergi integr
requir cultur process adapt synergi model forecast
risk estim remain integr unquantifi aspect target
forecast model margin eros could occur under-perform
increas risk amazon distribut busi like impact revenu
tmo laboratori product servic lp busi custom shown
will consid amazon vendor consum product expir
date beaker pipett expect amazon expertis logist suppli chain
allow amazon offer product competit cost thu impact lp revenu overal
dollar million except per share data
good sold
net incom continu op
sg sale
 sale
oper expens sale
compani report leerink partner estim
bp y/i bp
dilut pthn
end late aug
model
bp
